| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-04-08 | Domainex (UK) | nomination |
Technology - Services | Nomination | ||
| 2015-04-07 | Pfizer (USA - NY) Merck Serono, a Merck KGaA company (Germany) | avelumab (MSB0010718C) , Xalkori® (crizotinib), anti-PD-1 antibody | multiple types of cancer | development commercialisation co-promotion |
Cancer - Oncology | Development agreement |
| 2015-04-07 | Crispr Therapeutics (Switzerland - UK) | establishment of a new subsidiary in the US |
Genetic diseases - Rare diseases | Establishment of a new subsidiary in the US | ||
| 2015-04-07 | Vernalis (UK) Taisho Pharmaceutical (Japan) | novel antibiotics | R&D |
Infectious diseases | R&D agreement | |
| 2015-04-07 | Flamel Technologies (France) | resignation |
Resignation | |||
| 2015-04-07 | Taxus Cardium (USA - CA) Dr. Reddy's Laboratories (India) | Generx® (alferminogene tadenovec [Ad5FGF-4]) | refractory angina, myocardial ischemia due to cardiac microvascular insufficiency | licensing development commercialisation |
Cardiovascular diseases | Licensing agreement |
| 2015-04-07 | Amphivena Therapeutics (USA - CA) Janssen Biotech, a J&J company (USA - NJ) | development | Cancer - Oncology | Milestone | ||
| 2015-04-06 | BMS (USA - NY) uniQure (The Netherlands) | gene therapies for cardiovascular diseases | cardiovascular diseases | collaboration |
Cardiovascular diseases | Collaboration agreement |
| 2015-04-02 | GSK (UK) | new centre for vaccines R&D | opening of new premises | Infectious diseases | Opening of new premises | |
| 2015-04-02 | Grunenthal (Germany) Janssen Pharmaceuticals, a J&J company (USA - NJ) Depomed (USA - CA) | Nucynta® (tapentadol), Nucynta® ER (tapentadol) | management of moderate-to-severe acute pain in adults | product acquisition |
CNS diseases | Product acquisition |
| 2015-04-02 | Eli Lilly (USA - IN) OncoMed Pharmaceuticals (USA - CA) | demcizumab, Alimta® (pemetrexed for injection) | first-line advanced non-small cell lung cancer (NSCLC) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-04-01 | 4SC (Germany) | nomination |
Autoimmune diseases - Cancer - Oncology | Nomination | ||
| 2015-04-01 | Basilea Pharmaceutica (Switzerland) The Institute of Cancer Research (UK) Cancer Research Technology (UK) the Wellcome Trust (UK) The University of Manchester (UK) | panRAF kinase inhibitors | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-04-01 | Reneuron (UK) | nomination |
Regenerative medicine | Nomination | ||
| 2015-04-01 | Oxford Gene Technology (UK) Wellcome Trust Sanger Institute (UK) | data from the Deciphering Developmental Disorders (DDD) study | licensing |
Genetic diseases - Rare diseases | Licensing agreement | |
| 2015-04-01 | Eisai (Japan) Epizyme (USA - MA) | therapeutics targeting EZH2 including EPZ-6438 | development licensing commercialisation |
Cancer - Oncology - Rare diseases | Exercise of an option agreement | |
| 2015-04-01 | Neovacs (France) Stellar Biotechnologies (USA - CA) | Keyhole Limpet Hemocyanin (KLH) | services contract/supply agreement |
Technology - Services | Services contract | |
| 2015-04-01 | Immunogen (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-04-01 | Ipsen (France) | Ipsen Bioscience in Cambridge | opening of new premises | Opening of new premises | ||
| 2015-04-01 | Ipsen (France) Harvard University (USA - MA) | programs in the areas of neuroendocrine tumors, neuromuscular disorders, and platform technologies related to toxins and peptides | neuroendocrine tumors, neuromuscular disorders | R&D |
Cancer - Oncology - Neuromuscular diseases - Endocrinological diseases | R&D agreement |
